Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|October 14, 2011
Online access to latest application solutions
Shimadzu has launched two new tools giving online access to latest application solutions: a Special Edition of the customer magazine Shimadzu-News specifically for the needs of the pharmaceutical industry, and a News App for iPhone®and iPod® touch featuring the Shimadzu-News.
Advertisement
Shimadzu has launched two new tools giving online access to latest application solutions: a Special Edition of the customer magazine Shimadzu-News specifically for the needs of the pharmaceutical industry, and a News App for iPhone® and iPod® touch featuring the Shimadzu-News.
The 40 page Shimadzu News Pharma Special introduces solutions and applications for a multitude of topics such as drug research, development and testing as well as method development, manufacturing and quality control. The in-depth articles cover many disciplines of analytical instrumentation, e.g. chromatography, TOC and spectroscopy.
Shimadzu Pharma News is available for download at
News App for iPhone® and iPod® touch
Users of Apple mobile devices can now contact Shimadzu directly, independent of PC or notebook. Users benefit from an iOS optimized version of the customer magazine Shimadzu News for iPhone and iPod touch that even works on the iPad®. Additional functions such as overviews on markets or product related articles, an internal search function and the ‘MyShimadzu’ section complete the offer.
The News App can be downloaded from the
iPhone®, iPad® and iPod® are registered trademarks of Apple Inc. in the United States and/or other countries.
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement